Aprepitant and Nymalize (Nimodipine Oral Solution)
Determining the interaction of Aprepitant and Nymalize (Nimodipine Oral Solution) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Aprepitant may increase the blood levels and effects of niMODipine. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. According to the manufacturer, administration of the CYP450 3A4 substrate dexamethasone (20 mg orally on day 1 and 8 mg on days 2 through 5) in combination with aprepitant (125 mg single dose on day 1 and 80 mg/day on days 2 through 5) resulted in a 2.2-fold increase in dexamethasone systemic exposure (AUC) on days 1 and 5. Similarly, aprepitant increased the AUC of methylprednisolone (125 mg intravenously on day 1 and 40 mg orally on days 2 and 3) by 1.34-fold on day 1 and 2.5-fold on day 3. The effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.
MANAGEMENT: Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.
- "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.
- "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.
Generic Name: aprepitant
Brand name: Cinvanti, Emend, Emend 3-Day, Emend 2-Day
Synonyms: n.a.
Generic Name: nimodipine
Brand name: Nymalize, Nimotop
Synonyms: Nymalize
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aprepitant-NyQuil
- Aprepitant-Nyquil Cold & Flu
- Aprepitant-NyQuil Cold & Flu (Alcohol Free)
- Aprepitant-NyQuil Cough
- Aprepitant-NyQuil D
- Aprepitant-NyQuil Multi-Symptom
- Nymalize (Nimodipine Oral Solution)-Aprepitant Capsules
- Nymalize (Nimodipine Oral Solution)-Aprepitant Injection
- Nymalize (Nimodipine Oral Solution)-Aprepitant Intravenous
- Nymalize (Nimodipine Oral Solution)-Aprepitant Oral Suspension
- Nymalize (Nimodipine Oral Solution)-Aprepitant/Fosaprepitant Dimeglumine
- Nymalize (Nimodipine Oral Solution)-Apresazide